Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 24Terminated 4Withdrawn 3Unknown 3Recruiting 3Active not recruiting 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3NET 2Gastrointestinal 1

Conditions

Breast Neoplasms 111Carcinoma, Non-Small-Cell Lung 102Prostatic Neoplasms 66Multiple Myeloma 64Neoplasm Metastasis 63Colorectal Neoplasms 63Neoplasms 59Lung Neoplasms 52Leukemia, Myeloid, Acute 41Carcinoma, Hepatocellular 41Recurrence 40Lymphoma 40Leukemia, Lymphocytic, Chronic, B-Cell 36Pancreatic Neoplasms 34Melanoma 34Head and Neck Neoplasms 27Glioblastoma 26Rectal Neoplasms 25Ovarian Neoplasms 25Lymphoma, Large B-Cell, Diffuse 25Leukemia 24Brain Neoplasms 24Squamous Cell Carcinoma of Head and Neck 23Hematologic Neoplasms 23Carcinoma, Renal Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Myelodysplastic Syndromes 20Colonic Neoplasms 20Triple Negative Breast Neoplasms 19Lymphoma, Non-Hodgkin 19

Interventions

telotristat ethyl 1Panitumumab 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Carcinoid Tumor × Clear all
NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

British Columbia Cancer Agency

Phase 2 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

NCT04672876 2021-12-17

Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors

University of Chicago

Phase 2 Withdrawn
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT01172717 2013-07-26

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Boston Medical Center

Phase 2 Withdrawn
Endocrine

Carcinoid Tumor, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡